[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hypertrophic-cardiomyopathy-obstructive\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hypertrophic-cardiomyopathy-obstructive":74},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,50],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100625305",false,"NCT07420907","Study of the Progression of Chronic Cardiovascular Conditions","A Non-interventional Observational Study of the Sustained Use of Prolaio Digital Health Devices to Monitor the Natural History of Chronic Cardiovascular Conditions in Ambulatory Patients","OCORO","Inclusion Criteria:\n\n* 18 years of age and older\n* Ability to understand study assessments and give informed consent to data collection\n* Ability to comply with the study protocol\n* Ability to understand and respond to instructions in English\n* Has diagnosis of qualifying Cardiovascular Disease(s) (CVD) including but not limited to: HF, AS, HCM, HTN, DCM, etc.\n* Resides in the United States\n\nExclusion Criteria:\n\n* Allergy to adhesive used in biosensor patch\n* Life threatening disease process outside of area under study, such as actively treated cancer or pre\u002Fpost-transplant such as hepatic failure; end-stage renal disease.\n* Severe CVD defined by hospital admission for cardiac diagnosis within 30 days of enrollment or documentation of NYHA functional class IV\n* Self-reported weight of 400 pounds or greater","ALL","18 Years",{"count":19,"type":20},5000,"ESTIMATED","5 Years","OBSERVATIONAL","This study will collect physiologic data in patients with cardiovascular conditions and observe the natural history of those conditions for research purposes.",[25,26,27,28,29,30,31,32,33,34,35,36],"Cardiovascular Disease (CVD)","Heart Failure","Aortic Stenosis","Aortic Stenosis Disease","Hypertension","Hypertension (HTN)","Hypertrophic Cardiomyopathy Patients","Hypertrophic Cardiomyopathy Without Obstruction","Hypertrophic Cardiomyopathy, Obstructive","Dilated Cardiomyopathy (DCM)","Dilated Cardiomyopathy","Dilated Cardiomyopathy, Familial","RECRUITING","2026-02-16",{"date":40,"type":41},"2026-02-19","ACTUAL",{"date":43,"type":41},"2025-10-30",{"date":45,"type":20},"2030-10",{"name":47,"class":48},"Prolaio","INDUSTRY",1,{"id":51,"slug":4,"hasResults":10,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":5},"100593442","NCT07006493","REFINE-HCM: Intramyocardial Septal Radiofrequency Ablation for Obstructive Hypertrophic Cardiomyopathy","A Prospective, Multicenter, Randomized, Parallel-Controlled Superiority Study Evaluating the Efficacy and Safety of a Transcatheter Intramyocardial Septal Radiofrequency Ablation System in Patients With Obstructive Hypertrophic Cardiomyopathy","REFINE-HCM","Inclusion Criteria:\n\n* Age 18 to 80 years, regardless of sex\n* Diagnosed with obstructive hypertrophic cardiomyopathy (oHCM)\n* Presence of significant symptoms (e.g., dyspnea, chest pain, fatigue, palpitations, syncope)\n* NYHA class II or higher with LVOTG ≥50 mmHg at rest or provoked (assessed by echocardiography)\n* Septal thickness ≥15 mm\n* Unsuitable for surgical myectomy or refusal of surgery\n* Provided informed consent and agree to complete follow-up\n\nExclusion Criteria:\n\n* Asymptomatic or non-obstructive HCM\n* Septal thickness ≥30 mm\n* Mitral valve anatomy not suitable for ablation as judged by investigator\n* High risk of sudden cardiac death (SCD) requiring ICD implantation\n* Complete right bundle branch block at screening\n* Infective endocarditis, myocarditis, atrial myxoma, or intracardiac thrombus\n* Contraindication to transseptal access (e.g., septal patch)\n* Mechanical valves or history of aortic valve replacement\n* Severe heart failure with persistent symptoms and LVEF \\\u003C40%\n* Major cardiac events within 6 months (e.g., cardiac arrest, MI, heart failure hospitalization)\n* Significant structural heart disease requiring surgery\n* Prior septal reduction therapy or pacemaker implantation\n* Constrictive pericarditis or significant congenital heart disease\n* Bleeding disorders or contraindication to antithrombotic therapy\n* Liver dysfunction (ALT\u002FAST \\>3× ULN)\n* Renal insufficiency (creatinine \\>2.0 mg\u002FdL or on dialysis)\n* Pregnant, breastfeeding, or planning pregnancy within 6 months post-op\n* Life expectancy \\\u003C12 months\n* Participation in other investigational studies within 30 days or 5 half-lives\n* Investigator determines poor compliance or unsuitability\n* Contraindications to cardiac MRI (e.g., ICD, allergy to contrast, claustrophobia)","80 Years",{"count":59,"type":20},124,"INTERVENTIONAL",[62],"NA","This is a prospective, multicenter, randomized, parallel-controlled, superiority clinical trial designed to evaluate the efficacy and safety of a transcatheter intramyocardial septal radiofrequency ablation system for the treatment of patients with obstructive hypertrophic cardiomyopathy (oHCM). Eligible participants will be randomized in a 2:1 ratio to receive either active ablation under intracardiac echocardiographic guidance or a sham procedure. All participants will continue to receive standard-of-care medical therapy during the study period. The primary endpoint is the treatment effectiveness rate at 6 months, defined as a ≥50% reduction in LVOT gradient from baseline or a resting LVOT gradient \\\u003C30 mmHg.",[33],"2025-12-05",{"date":67,"type":41},"2025-12-15",{"date":69,"type":41},"2025-07-20",{"date":71,"type":20},"2027-12-30",{"name":73,"class":48},"SuZhou Sinus Medical Technologies Co.,Ltd",""]